<p>BioCryst 製藥（NASDAQ:BCRX - 獲取免費報告）在週一發佈的研究報告中，HC Wainwright 將其目標價格從 30.00 美元上調至 32.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “買入” 評級。HC Wainwright 的目標價格暗示該公司股價有 321.33% 的潛在上漲空間。</p>
<p>其他幾位研究分析師也最近對 BCRX 發表了評論。Evercore ISI 在 10 月 1 日的報告中重申了 “持平” 評級，並對 BioCryst 製藥的股票設定了 8.00 美元的目標價格。Needham &amp; Company LLC 在 11 月 4 日的研究報告中將 BioCryst 製藥的目標價格從 20.00 美元下調至 18.00 美元，並對該公司給予 “買入” 評級。Cantor Fitzgerald 在 10 月 15 日的報告中將 BioCryst 製藥的目標價格從 24.00 美元上調至 26.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 12 月 2 日的研究報告中重申了對 BioCryst 製藥的 “賣出（e+）” 評級。最後，Citizens Jmp 在 11 月 5 日的研究報告中將 BioCryst 製藥的目標價格從 27.00 美元下調至 25.00 美元，並對該股票給予 “市場表現優於大盤” 評級。十位分析師對該股票給予了買入評級，三位給予了持平評級，一位給予了賣出評級。根據 MarketBeat 的數據，BioCryst 製藥目前的平均評級為 “適度買入”，共識目標價格為 19.50 美元。</p>
<p><strong>獲取我們關於 BioCryst 製藥的最新股票報告</strong></p>
<h2>BioCryst 製藥股票表現</h2>
<p>週一中午交易時，BCRX 股票上漲 0.03 美元，達到 7.60 美元。該股票交易量為 1,874,402 股，而其平均交易量為 4,014,464 股。該公司的 50 日簡單移動平均線為 7.15 美元，200 日簡單移動平均線為 8.22 美元。該公司的市值為 16 億美元，市盈率為-152.06，貝塔值為 0.91。BioCryst 製藥的 12 個月低點為 6.00 美元，12 個月高點為 11.31 美元。</p>
<p>BioCryst 製藥（NASDAQ:BCRX - 獲取免費報告）在 11 月 3 日發佈了其季度財報。這家生物技術公司報告本季度每股收益為 0.06 美元，低於共識預期的 0.07 美元（差額為 0.01 美元）。BioCryst 製藥的股本回報率為-4.24%，淨利潤率為-1.46%。該公司本季度的收入為 1.594 億美元，而共識預期為 1.6291 億美元。去年同期，該公司每股收益為-0.07 美元。與去年同期相比，BioCryst 製藥的收入增長了 36.1%。分析師預測 BioCryst 製藥在當前年度的每股收益將為-0.36 美元。</p>
<h2>內部買賣</h2>
<p>在相關消息中，內部人士 Alane P. Barnes 在 12 月 3 日的交易中出售了 19,770 股公司的股票。該股票以平均價格 7.65 美元出售，總價值為 151,240.50 美元。出售完成後，該內部人士持有 345,476 股公司股票，價值約為 2,642,891.40 美元。這代表其持股比例減少了 5.41%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。在過去三個月中，內部人士共出售了價值 1,164,401 美元的 161,680 股公司股票。目前，內部人士持有該股票的比例為 5.10%。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者最近買入和賣出了該股票的股份。Deerfield Management Company L.P.在第三季度將其在 BioCryst 製藥的股份增加了 159.4%。Deerfield Management Company L.P.目前擁有 12,169,000 股該生物技術公司的股票，價值 92,363,000 美元，此前在上個季度又購買了 7,477,000 股。Arrowstreet Capital Limited Partnership 在第二季度將其在 BioCryst 製藥的持股增加了 2,103.7%。Arrowstreet Capital Limited Partnership 目前擁有 4,278,555 股該生物技術公司的股票，價值 38,336,000 美元，此前在上個季度又收購了 4,084,403 股。Assenagon Asset Management S.A.在第二季度將其在 BioCryst 製藥的股份增加了 25,631.2%。Assenagon Asset Management S.A.目前擁有 3,620,637 股該生物技術公司的股票，價值 32,441,000 美元，此前在上個季度又收購了 3,606,566 股。Millennium Management LLC 在第一季度將其在 BioCryst 製藥的股份增加了 382.6%。Millennium Management LLC 目前擁有 3,812,874 股該生物技術公司的股票，價值 28,597,000 美元，此前在上個季度又購買了 3,022,769 股。最後，Qube Research &amp; Technologies Ltd 在第二季度將其在 BioCryst 製藥的持股增加了 152.3%。Qube Research &amp; Technologies Ltd 目前擁有 2,373,489 股該生物技術公司的股票，價值 21,266,000 美元，此前在上個季度又購買了 1,432,824 股。機構投資者目前持有該公司 85.88% 的股票。</p>
<h2>關於 BioCryst 製藥</h2>
<p>（獲取免費報告）</p>
<p>BioCryst 製藥公司是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司市場上銷售的藥物包括用於治療急性非複雜流感的靜脈注射神經氨酸酶抑制劑 peramivir，品牌名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑 ORLADEYO。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 BioCryst Pharmaceuticals</li>
<li>投資汽車股票</li>
<li>超級微型公司的拋售是海市蜃樓——以下是為什麼反彈可能會迅速回歸的原因</li>
<li>加拿大債券市場假期：如何投資和交易</li>
<li>3 家公司將大現金流轉化為更大的股東收益</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>GOOGL 的不可阻擋的勢頭將價格目標推至歷史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 BioCryst Pharmaceuticals 嗎？</h2>
<p>在考慮 BioCryst Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 BioCryst Pharmaceuticals 並不在名單上。</p>
<p>雖然 BioCryst Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BioCryst制藥

<p>HC Wainwright 將 BioCryst Pharmaceuticals 的目標價格從 30 美元上調至 32 美元，維持 “買入” 評級，暗示潛在上漲幅度為 321.33%。其他分析師的評級各不相同，平均共識為 “適度買入”，目標價為 19.50 美元。BioCryst 的股票表現略有上升，內部人士和機構活動有所記錄。儘管未能達到每股收益預期，該公司報告的收入同比增長 36.1%</p>

<p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price lifted by research analysts at HC Wainwright from $30.00 to $32.00 in a research report issued on Monday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 321.33% from the company's previous close.</p>
<div class="lb-trans"><p>BioCryst 製藥（NASDAQ:BCRX - 獲取免費報告）在週一發佈的研究報告中，HC Wainwright 將其目標價格從 30.00 美元上調至 32.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “買入” 評級。HC Wainwright 的目標價格暗示該公司股價有 321.33% 的潛在上漲空間。</p>
</div><p>Several other research analysts have also recently commented on BCRX. Evercore ISI reiterated an &#34;in-line&#34; rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Needham &amp; Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, December 2nd. Finally, Citizens Jmp decreased their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.50.</p>
<div class="lb-trans"><p>其他幾位研究分析師也最近對 BCRX 發表了評論。Evercore ISI 在 10 月 1 日的報告中重申了 “持平” 評級，並對 BioCryst 製藥的股票設定了 8.00 美元的目標價格。Needham &amp; Company LLC 在 11 月 4 日的研究報告中將 BioCryst 製藥的目標價格從 20.00 美元下調至 18.00 美元，並對該公司給予 “買入” 評級。Cantor Fitzgerald 在 10 月 15 日的報告中將 BioCryst 製藥的目標價格從 24.00 美元上調至 26.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 12 月 2 日的研究報告中重申了對 BioCryst 製藥的 “賣出（e+）” 評級。最後，Citizens Jmp 在 11 月 5 日的研究報告中將 BioCryst 製藥的目標價格從 27.00 美元下調至 25.00 美元，並對該股票給予 “市場表現優於大盤” 評級。十位分析師對該股票給予了買入評級，三位給予了持平評級，一位給予了賣出評級。根據 MarketBeat 的數據，BioCryst 製藥目前的平均評級為 “適度買入”，共識目標價格為 19.50 美元。</p>
</div><p><strong>Get Our Latest Stock Report on BioCryst Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 BioCryst 製藥的最新股票報告</strong></p>
</div><h2>BioCryst Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>BioCryst 製藥股票表現</h2>
</div><p>Shares of BCRX stock traded up $0.03 during mid-day trading on Monday, hitting $7.60. 1,874,402 shares of the stock traded hands, compared to its average volume of 4,014,464. The company's 50-day simple moving average is $7.15 and its 200-day simple moving average is $8.22. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -152.06 and a beta of 0.91. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31.</p>
<div class="lb-trans"><p>週一中午交易時，BCRX 股票上漲 0.03 美元，達到 7.60 美元。該股票交易量為 1,874,402 股，而其平均交易量為 4,014,464 股。該公司的 50 日簡單移動平均線為 7.15 美元，200 日簡單移動平均線為 8.22 美元。該公司的市值為 16 億美元，市盈率為-152.06，貝塔值為 0.91。BioCryst 製藥的 12 個月低點為 6.00 美元，12 個月高點為 11.31 美元。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter last year, the firm posted ($0.07) earnings per share. BioCryst Pharmaceuticals's revenue was up 36.1% compared to the same quarter last year. Analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>BioCryst 製藥（NASDAQ:BCRX - 獲取免費報告）在 11 月 3 日發佈了其季度財報。這家生物技術公司報告本季度每股收益為 0.06 美元，低於共識預期的 0.07 美元（差額為 0.01 美元）。BioCryst 製藥的股本回報率為-4.24%，淨利潤率為-1.46%。該公司本季度的收入為 1.594 億美元，而共識預期為 1.6291 億美元。去年同期，該公司每股收益為-0.07 美元。與去年同期相比，BioCryst 製藥的收入增長了 36.1%。分析師預測 BioCryst 製藥在當前年度的每股收益將為-0.36 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, insider Alane P. Barnes sold 19,770 shares of the company's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total value of $151,240.50. Following the completion of the sale, the insider owned 345,476 shares in the company, valued at approximately $2,642,891.40. This represents a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 161,680 shares of company stock worth $1,164,401. 5.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Alane P. Barnes 在 12 月 3 日的交易中出售了 19,770 股公司的股票。該股票以平均價格 7.65 美元出售，總價值為 151,240.50 美元。出售完成後，該內部人士持有 345,476 股公司股票，價值約為 2,642,891.40 美元。這代表其持股比例減少了 5.41%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。在過去三個月中，內部人士共出售了價值 1,164,401 美元的 161,680 股公司股票。目前，內部人士持有該股票的比例為 5.10%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. raised its stake in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock worth $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after acquiring an additional 4,084,403 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock worth $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter. Millennium Management LLC boosted its stake in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after buying an additional 3,022,769 shares in the last quarter. Finally, Qube Research &amp; Technologies Ltd grew its holdings in shares of BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Institutional investors own 85.88% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近買入和賣出了該股票的股份。Deerfield Management Company L.P.在第三季度將其在 BioCryst 製藥的股份增加了 159.4%。Deerfield Management Company L.P.目前擁有 12,169,000 股該生物技術公司的股票，價值 92,363,000 美元，此前在上個季度又購買了 7,477,000 股。Arrowstreet Capital Limited Partnership 在第二季度將其在 BioCryst 製藥的持股增加了 2,103.7%。Arrowstreet Capital Limited Partnership 目前擁有 4,278,555 股該生物技術公司的股票，價值 38,336,000 美元，此前在上個季度又收購了 4,084,403 股。Assenagon Asset Management S.A.在第二季度將其在 BioCryst 製藥的股份增加了 25,631.2%。Assenagon Asset Management S.A.目前擁有 3,620,637 股該生物技術公司的股票，價值 32,441,000 美元，此前在上個季度又收購了 3,606,566 股。Millennium Management LLC 在第一季度將其在 BioCryst 製藥的股份增加了 382.6%。Millennium Management LLC 目前擁有 3,812,874 股該生物技術公司的股票，價值 28,597,000 美元，此前在上個季度又購買了 3,022,769 股。最後，Qube Research &amp; Technologies Ltd 在第二季度將其在 BioCryst 製藥的持股增加了 152.3%。Qube Research &amp; Technologies Ltd 目前擁有 2,373,489 股該生物技術公司的股票，價值 21,266,000 美元，此前在上個季度又購買了 1,432,824 股。機構投資者目前持有該公司 85.88% 的股票。</p>
</div><h2>About BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 BioCryst 製藥</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst 製藥公司是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司市場上銷售的藥物包括用於治療急性非複雜流感的靜脈注射神經氨酸酶抑制劑 peramivir，品牌名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑 ORLADEYO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Investing In Automotive Stocks</li>
<li>Super Micro's Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 BioCryst Pharmaceuticals</li>
<li>投資汽車股票</li>
<li>超級微型公司的拋售是海市蜃樓——以下是為什麼反彈可能會迅速回歸的原因</li>
<li>加拿大債券市場假期：如何投資和交易</li>
<li>3 家公司將大現金流轉化為更大的股東收益</li>
<li>高飛者：2022 年 3 月的 3 只天然氣股票</li>
<li>GOOGL 的不可阻擋的勢頭將價格目標推至歷史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 BioCryst Pharmaceuticals 嗎？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 BioCryst Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 BioCryst Pharmaceuticals 並不在名單上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioCryst Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 預測 BioCryst 製藥（NASDAQ:BCRX）股票將出現強勁的價格升值